We use cookies to improve your experience. By continuing to browse this site, you accept our cookie policy.×
Skip main navigation
Open Drawer MenuClose Drawer Menu
Aging Health
Bioelectronics in Medicine
Biomarkers in Medicine
Breast Cancer Management
CNS Oncology
Colorectal Cancer
Concussion
Epigenomics
Future Cardiology
Future Medicine AI
Future Microbiology
Future Neurology
Future Oncology
Future Rare Diseases
Future Virology
Hepatic Oncology
HIV Therapy
Immunotherapy
International Journal of Endocrine Oncology
International Journal of Hematologic Oncology
Journal of 3D Printing in Medicine
Lung Cancer Management
Melanoma Management
Nanomedicine
Neurodegenerative Disease Management
Pain Management
Pediatric Health
Personalized Medicine
Pharmacogenomics
Regenerative Medicine
Supplement

When nonplatinum is the answer: the role of trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer

    Nicoletta Colombo

    *Author for correspondence:

    E-mail Address: nicoletta.colombo@ieo.it

    European Institute of Oncology, University of Milan-Bicocca, via Ripamonti 435, Milan, Italy

    Search for more papers by this author

    Published Online:11 Oct 2017https://doi.org/10.2217/fon-2017-0319

    Abstract

    Trabectedin + pegylated liposomal doxorubicin (PLD) offers a well tolerated and effective nonplatinum, nontaxane alternative for treatment of ovarian cancer patients with a treatment-free interval after platinum beyond 6 months, especially for those relapsing between 6 and 12 months and those who are not candidates to receive platinum-based therapy. Using the nonplatinum trabectedin + PLD combination gives patients time to recover from platinum-related toxicities and may restore platinum sensitivity in tumor cells. The sequence effect, by which intercalation of trabectedin + PLD between platinum regimens may enhance the activity of next platinum and improve survival, is currently under investigation in the Phase III prospective INternational OVArian cancer patients Trial with YONdelis.

    References

    • 1 Wilson MK, Pujade-Lauraine E, Aoki D et al. Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease. Ann. Oncol. 28(4), 727–732 (2017).
      Medline CASGoogle Scholar
    • 2 Pignata S, De Placido S, Biamonte R et al. Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: the Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study. BMC Cancer 6, 5 (2006).
      MedlineGoogle Scholar
    • 3 Markman M, Kennedy A, Webster K et al. Clinical features of hypersensitivity reactions to carboplatin. J. Clin. Oncol. 17(4), 1141 (1999).
      Medline CASGoogle Scholar
    • 4 Gadducci A, Tana R, Teti G et al. Analysis of the pattern of hypersensitivity reactions in patients receiving carboplatin retreatment for recurrent ovarian cancer. Int. J. Gynecol. Cancer 18(4), 615–620 (2008).
      Medline CASGoogle Scholar
    • 5 Gomez R, Harter P, Lück HJ et al. Carboplatin hypersensitivity: does introduction of skin test and desensitization reliably predict and avoid the problem? A prospective single-center study. Int. J. Gynecol. Cancer 19(7), 1284–1287 (2009).
      MedlineGoogle Scholar
    • 6 O'Cearbhaill R, Zhou Q, Iasonos A et al. The prophylactic conversion to an extended infusion schedule and use of premedication to prevent hypersensitivity reactions in ovarian cancer patients during carboplatin retreatment. Gynecol. Oncol. 116(3), 326–331 (2010).
      MedlineGoogle Scholar
    • 7 Joly F, Ray-Coquard I, Fabbro M et al. Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared with carboplatin-paclitaxel combination: analysis from the GCIG CALYPSO relapsing ovarian cancer trial. Gynecol. Oncol. 122(2), 226–232 (2011).
      Medline CASGoogle Scholar
    • 8 Moon DH, Lee JM, Noonan AM et al. Deleterious BRCA1/2 mutation is an independent risk factor for carboplatin hypersensitivity reactions. Br. J. Cancer 109(4), 1072–1078 (2013).
      Medline CASGoogle Scholar
    • 9 Monk BJ, Herzog TJ, Kaye SB et al. Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer. J. Clin. Oncol. 28(19), 3107–3114 (2010).
      Medline CASGoogle Scholar
    • 10 Monk BJ, Ghatage P, Parekh T et al. Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the Phase III OVA-301 study. Ann. Oncol. 26(5), 914–920 (2015).
      Medline CASGoogle Scholar
    • 11 European Medicines Agency (EMA). Assessment report for Yondelis (EPAR) (2009). www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000773/WC500059175.pdf.
      Google Scholar
    • 12 Krasner CN, Poveda A, Herzog TJ et al. Patient-reported outcomes in relapsed ovarian cancer: results from a randomized Phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD alone. Gynecol. Oncol. 127(1), 161–167 (2012).
      Medline CASGoogle Scholar
    • 13 González Martín A. Safety profile of trabectedin in combination with liposomal pegylated doxorubicin in relapsed ovarian carcinoma: considerations for optimal management. Int. J. Gynecol. Cancer 21(Suppl. 1), S6–S8 (2011).
      MedlineGoogle Scholar
    • 14 Sehouli J, Alfaro V, González-Martín A. Trabectedin plus pegylated liposomal doxorubicin in the treatment of patients with partially platinum-sensitive ovarian cancer: current evidence and future perspectives. Ann. Oncol. 23(3), 556–562 (2012).
      Medline CASGoogle Scholar
    • 15 Romero I, Colombo N, Kaye SB et al. Tolerability of long-term use of trabectedin in combination with pegylated liposomal doxorubicin (PLD) in patients with relapsed ovarian cancer (ROC). J. Clin. Oncol. 28(Suppl. 15), 5121 (2010).
      Google Scholar
    • 16 Vergote I, Vermorken J, Pujade Lauraine E et al. Safety analysis of trabectedin in combination with pegylated liposomal doxorubicin (PLD) vs PLD alone in ovarian cancer patients 65 years of age and older. Eur. J. Cancer Suppl. 7(2), 458 (2009).
      Google Scholar
    • 17 Nicoletto MO, Baldoni A, Casarin A et al. Trabectedin plus pegylated liposomal doxorubicin: retrospective analysis in heavily pretreated platinum-sensitive ovarian cancer. Tumori 101(5), 506–510 (2015).
      Medline CASGoogle Scholar
    • 18 Gounaris I, Hatcher HM, Davidson D et al. Trabectedin for advanced soft tissue sarcomas: a single institution experience. Future Oncol. 10(11), 1843–1851 (2014).
      CASGoogle Scholar
    • 19 Leporini C, Patanè M, Saullo F et al. A comprehensive safety evaluation of trabectedin and drug–drug interactions of trabectedin-based combinations. BioDrugs 28(6), 499–511 (2014).
      Medline CASGoogle Scholar
    • 20 Vergote I, Meerpohl HG, Boman K et al. Exploratory study of platinum-sensitive (ps) patients who did not achieve a complete response after first-line platinum-based treatment before ova-301 trial. Int. J. Gynecol. Cancer 22(8 Suppl. 3), 225 (2012).
      Google Scholar
    • 21 Pignata S, Cannella L, Leopardo D et al. Chemotherapy in epithelial ovarian cancer. Cancer Lett. 303(2), 73–83 (2011).
      Medline CASGoogle Scholar
    • 22 Monk BJ, Herzog TJ, Kaye SB et al. Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: overall survival analysis. Eur. J. Cancer 48(15), 2361–2368 (2012).
      Medline CASGoogle Scholar
    • 23 Poveda A, Ray-Coquard I, Romero I et al. Emerging treatment strategies in recurrent platinum-sensitive ovarian cancer: focus on trabectedin. Cancer Treat. Rev. 40(3), 366–375 (2014).
      Medline CASGoogle Scholar
    • 24 Larsen AK, Galmarini CM, D'Incalci M. Unique features of trabectedin mechanism of action. Cancer Chemother. Pharmacol. 77(4), 663–671 (2016).
      Medline CASGoogle Scholar
    • 25 Colmegna B, Uboldi S, Erba E et al. Resistance to minor groove binders. Drug Discov. Today Technol. 11, 73–79 (2014).
      MedlineGoogle Scholar
    • 26 Colmegna B, Uboldi S, Frapolli R et al. Increased sensitivity to platinum drugs of cancer cells with acquired resistance to trabectedin. Br. J. Cancer 113(12), 1687–1693 (2015).
      Medline CASGoogle Scholar
    • 27 Horowitz N, Hua J, Gibb RK et al. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model. Gynecol. Oncol. 94(1), 67–73 (2004).
      Medline CASGoogle Scholar
    • 28 Cohen S, Bruchim I, Graiver D et al. Platinum-resistance in ovarian cancer cells is mediated by IL-6 secretion via the increased expression of its target cIAP-2. J. Mol. Med. (Berl.) 91(3), 357–368 (2013).
      Medline CASGoogle Scholar
    • 29 Wang Y, Niu XL, Qu Y et al. Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells. Cancer Lett. 295(1), 110–123 (2010).
      Medline CASGoogle Scholar
    • 30 Allavena P, Signorelli M, Chieppa M et al. Anti-inflammatory properties of the novel antitumor agent Yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production. Cancer Res. 65(7), 2964–2971 (2005).
      Medline CASGoogle Scholar
    • 31 Germano G, Frapolli R, Simone M et al. Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells. Cancer Res. 70(6), 2235–2244 (2010).
      Medline CASGoogle Scholar
    • 32 Kaye SB, Colombo N, Monk BJ et al. Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval. Ann. Oncol. 22(1), 49–58 (2011).
      Medline CASGoogle Scholar
    • 33 ClinicalTrials database: NCT01379989. https://clinicaltrials.gov/ct2/show/NCT01379989.
      Google Scholar